Pharma major Lupin Limited (Lupin) announced the launch of Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid® Tablets.

It is indicated for Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

It is also used for Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Levothyroxine Sodium Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg had an annual sale of approximately USD 2.5 billions in the U.S (IQVIA MAT January 2019).